Payment overview · 2025
General Payments
$1,211.32
59 reported records · 11 companies
Healthcare provider profile · identity verified
Xin Tan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1235117979
Verified facts
What the public records show
CMS Open Payments records show Xin Tan, M.D. received $1,211.32 in general payments during 2025 across 59 reported records.
Ardelyx, Inc. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Ibsrela, Linzess, Rybelsus, Voquezna.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Ardelyx, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBSRELA as an associated drug or biological on 59980 records involving 18215 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ibsrela by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nexium by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vemlidy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Rybelsus by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Voquezna by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $203.76 | 16.8% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $203.17 | 16.8% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $195.88 | 16.2% | 9 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $186.01 | 15.4% | 10 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $145.05 | 12.0% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.82 | 8.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.80 | 5.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.72 | 3.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.87 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.50 | 1.8% | 1 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $20.74 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,211.32 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $203.76 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $203.17 | 9 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $145.05 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.82 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $102.82 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $100.45 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.80 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.80 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.85 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $46.72 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $45.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 294 | exact normalized | Medicare Part D |
| IBSRELA ibsrela |
2025 | Ibsrela | 2024 | 98 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 55 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 110 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
294 | 43 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Ardelyx, Inc. Exact reporting entity; no affiliate inference |
2025 | IBSRELA open payments reported associated product |
CMS Open Payments — General Payments 59980 supporting records · 18215 recipient NPIs · example record 1247828901 |
Ibsrela · 2024 Exact normalized brand match · 1 Part D row |
98 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
110 | 17 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 1246 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1076 | 136 |
| Losartan Potassium | Losartan Potassium | 740 | 93 |
| Diclofenac Epolamine | Diclofenac Epolamine | 712 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 523 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 483 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 406 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 405 | 58 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 381 | 53 |
| Metformin Hcl | Metformin Hcl | 369 | 55 |
| Alendronate Sodium | Alendronate Sodium | 364 | 46 |
| Donepezil Hcl | Donepezil Hcl | 344 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 331 | 79 |
| Omeprazole | Omeprazole | 330 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 326 | 91 |
| Celecoxib | Celecoxib | 323 | 53 |
| Finasteride | Finasteride | 321 | 42 |
| Restasis | Cyclosporine | 319 | 50 |
| Creon | Lipase/Protease/Amylase | 294 | 43 |
| Simvastatin | Simvastatin | 286 | 35 |
| Azithromycin | Azithromycin | 261 | 128 |
| Gabapentin | Gabapentin | 229 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 221 | 51 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 216 | 39 |
| Ammonium Lactate | Ammonium Lactate | 209 | 43 |
| Sucralfate | Sucralfate | 203 | 39 |
| Famotidine | Famotidine | 195 | 35 |
| Halobetasol Propionate | Halobetasol Propionate | 195 | 47 |
| Nitroglycerin | Nitroglycerin | 194 | 39 |
| Mometasone Furoate | Mometasone Furoate | 184 | 51 |
| Meloxicam | Meloxicam | 179 | 50 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 178 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 44 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 173 | 40 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 162 | 23 |
| Atenolol | Atenolol | 154 | 20 |
| Icosapent Ethyl | Icosapent Ethyl | 151 | 99 |
| Hydrocortisone | Hydrocortisone | 150 | 36 |
| Ketoconazole | Ketoconazole | 149 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 149 | 31 |
| Trazodone Hcl | Trazodone Hcl | 146 | 23 |
| Azelastine Hcl | Azelastine Hcl | 144 | 27 |
| Tacrolimus | Tacrolimus | 138 | 19 |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 128 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 119 | 30 |
| Raloxifene Hcl | Raloxifene Hcl | 117 | 11 |
| Alprazolam | Alprazolam | 112 | 15 |
| Rybelsus | Semaglutide | 110 | 17 |
| Meclizine Hcl | Meclizine Hcl | 109 | 43 |
| Furosemide | Furosemide | 106 | 19 |
| Procto-Med Hc | Hydrocortisone | 101 | 25 |
| Ibsrela | Tenapanor Hcl | 98 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 12 |
| Myrbetriq | Mirabegron | 92 | 14 |
| Telmisartan | Telmisartan | 92 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 11 |
| Lactulose | Lactulose | 89 | 30 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 88 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 79 | 18 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 78 | 16 |
| Januvia | Sitagliptin Phosphate | 74 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 73 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 69 | 18 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 68 | suppressed |
| Spironolactone | Spironolactone | 65 | suppressed |
| Amoxicillin | Amoxicillin | 63 | 36 |
| Lisinopril | Lisinopril | 63 | suppressed |
| Cyclosporine | Cyclosporine | 62 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 11 |
| Memantine Hcl | Memantine Hcl | 61 | suppressed |
| Folic Acid | Folic Acid | 58 | 20 |
| Montelukast Sodium | Montelukast Sodium | 58 | suppressed |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 56 | suppressed |
| Linzess | Linaclotide | 55 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 12 |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 53 | 21 |
| Allopurinol | Allopurinol | 51 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 51 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 50 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 17 |
| Erythromycin | Erythromycin Base | 45 | 21 |
| Fluocinonide | Fluocinonide | 45 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 45 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | suppressed |
| Prednisone | Prednisone | 43 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 30 |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Loperamide | Loperamide Hcl | 41 | 32 |
| Ranolazine Er | Ranolazine | 41 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Voquezna | Vonoprazan Fumarate | 40 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Denta 5000 Plus | Fluoride (Sodium) | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | suppressed |
| Lidocaine | Lidocaine | 37 | suppressed |
| Mesalamine | Mesalamine | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 25 |
| Carvedilol | Carvedilol | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Ciclopirox | Ciclopirox | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 26 |
| Latanoprost | Latanoprost | 28 | suppressed |
| Nexium | Esomeprazole Magnesium | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 27 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 26 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 26 | suppressed |
| Jublia | Efinaconazole | 25 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 24 | suppressed |
| Ramelteon | Ramelteon | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Neupro | Rotigotine | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 15 |
| Scopolamine | Scopolamine | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Clarithromycin | Clarithromycin | 14 | 11 |
| Enulose | Lactulose | 14 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 14 | suppressed |
| Proctozone-Hc | Hydrocortisone | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,211.32 · 59 records | Ardelyx, Inc. | AIRSUPRA, CAPLYTA, CREON, GEMTESA, IBSRELA, LINZESS, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VELPHORO, VOQUEZNA, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error